Low-dose semaglutide for weight loss in obese Pakistani adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label, single-arm pilot interventional study will enroll 60 obese Pakistani adults without type 2 diabetes at a single center in Hyderabad. Participants will receive once-weekly subcutaneous semaglutide with stepwise titration (0.25 mg for 4 weeks, 0.5 mg for 4 weeks, then 1.0 mg for 16 weeks) alongside standardized hypocaloric diet and lifestyle counseling for a total of 24 weeks. Primary outcomes include weight loss and changes in cardiometabolic risk factors, with safety monitored through laboratory testing and adverse event reporting. The trial aims to generate locally relevant data on the effectiveness and tolerability of lower-dose semaglutide in a South Asian, non-diabetic population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18 years or older.
* Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs.
* No diagnosis of type 2 diabetes mellitus, confirmed by:

Fasting blood glucose \< 126 mg/dL, and HbA1c \< 6.5% within three months prior to enrollment.

* Willingness and ability to provide written informed consent.
* Willingness to comply with study procedures, including weekly injections and lifestyle counseling.

Exclusion Criteria:

* History of pancreatitis.
* History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
* Pregnant or lactating women.
* Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or hepatic impairment (ALT or AST \> 3× upper limit of normal).
* Current use of other anti-obesity medications.
* Known hypersensitivity to semaglutide or any component of the formulation.
* Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.

Where it's running

• Asian Institute of Medical Sciences
  Hyderābād, Sindh, Pakistan Recruiting

Study contacts

• Principal investigator: Sadik Memon — Asian Institute Of Medical Sciences
• Study coordinator: Fatima Nadeem Dr, Pharm-D, Mphil
• Email: fatima.nadeem2401@gmail.com
• Phone: +923080744996

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.